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Total clearance of the T. cruzi infection e referred to herein as “sterile cure” e seems to be a critical
prerequisite for new drug candidates for Chagas disease, ensuring long-term beneﬁcial effects for pa-
tients in the chronic indeterminate stage. This requirement is notably supported by the recent ﬁndings of
clinical studies involving posaconazole and fosravuconazole, where the majority of patients treated
eventually relapsed after an apparent clearance of parasitaemia at the end of treatment. We have
adapted an in vitro system to predict the ability of a compound to deliver sterile cure. It relies on mouse
peritoneal macrophages as host cells for Trypanosoma cruzi amastigotes. The macrophages do not pro-
liferate, allowing for long-term testing and wash-out experiments. Giemsa staining followed by micro-
scopy provides a highly sensitive and speciﬁc tool to quantify the numbers of infected host cells.
Combining macrophages as host cells and Giemsa staining as the read-out, we demonstrate that pos-
aconazole and other CYP51 inhibitors are unable to achieve complete clearance of an established T. cruzi
infection in vitro in spite of the fact that these compounds are active at signiﬁcantly lower concentrations
than the reference drugs benznidazole and nifurtimox. Indeed, a few macrophages remained infected
after 96 h of drug incubation in the presence of CYP51 inhibitorsealbeit at a very low parasite load. These
residual T. cruzi amastigotes were shown to be viable and infective, as demonstrated by wash-out ex-
periments. We advocate characterizing any new anti-T. cruzi early stage candidates for sterile cidality
early in the discovery cascade, as a surrogate for delivery of sterile cure in vivo.
© 2016 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Trypanosoma cruzi is the causative agent of Chagas disease,
endemic in 21 countries of Latin America (WHO, 2015). Migration
and travel have additionally contributed to the spread of Chagas
disease to other continents, including North America and Europe.
The World Health Organization estimates that 6e7 million people
are infected world-wide, leading to more than 10,000 deaths
annually (WHO fact sheet 340). In the absence of a vaccine, the only
treatment option is chemotherapy. However, the existing drugs
benznidazole and nifurtimox have several limitations, notably in
relation to their severe adverse effects and contraindications
(Andrade et al., 1992; Bahia-Oliveira et al., 2000; Cancado, 2002;
Urbina, 2010). Safer drugs are urgently needed. Over the last few
years, the development of new anti-T. cruzi agents has focused onHealth Institute, Socinstrasse
r).
Ltd on behalf of Australian Society fazoles as inhibitors of CYP450-dependent lanosterol demethylase
(CYP51; 1.14.13.70) that act by blocking trypanosomatida ergosterol
synthesis (Buckner and Urbina, 2012; Chatelain, 2015). Azoles
display remarkable nanomolar range in vitro potency against
T. cruzi as well as a good safety proﬁle in humans (Buckner and
Urbina, 2012; Soeiro Mde et al., 2013). Azoles have been in use as
antifungal agents for decades, which has greatly facilitated their
preclinical development for Chagas disease. Recently, the two tri-
azoles posaconazole and fosravuconazole, a prodrug of rav-
uconazole, were tested in controlled clinical phase II studies
(Urbina, 2015). However, both molecules failed to show sufﬁcient
levels of efﬁcacy in chronic Chagas patients; after an initial phase of
apparent clearance of parasitaemia following the end of treatment,
80% of the patients relapsed 10 months after the end of treatment
in the posaconazole (CHAGAZASOL) study (Molina et al., 2014),
while 71% relapsed 12 months after the end of treatment in the
fosravuconazole study (Torrico, 2013), as determined by real time
qPCR detection of T. cruzi DNA. These disappointing clinical results
for azoles contrast with the relatively low treatment failuresor Parasitology. This is an open access article under the CC BY-NC-ND license (http://
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clearance of parasites at the same endpoint in the posaconazole and
fosravuconazole trials respectively. The outcome of a clinical trial
depends on several factors, pharmacokinetics and host immune
system play an important role. The obtained posaconazole levels in
patients treated with 100e400 mg b. i.d. were clearly below the
plasma levels in mice (20 mg/kg/day) (Urbina, 2015). A prolonged
treatment duration and a higher dose or an improved formulation
to get higher plasma levels could lead to a better clinical outcome.
While the full potential of azoles for combination chemotherapy
has not yet been realized (Fügi et al., 2015), our working hypothesis,
derived from the disappointing outcome of the clinical trials, is that
any novel anti-T. cruzi hit or chemistry starting point emerging from
the discovery pipeline should be assessed at an early stage for its
potential to deliver sterile cidality against different T. cruzi geno-
types (Moraes et al., 2014; Chatelain, 2015). Our aim is to develop
an in vitro test for sterile cidality towards T. cruzi amastigotes.
Posaconazole and benznidazole can serve as benchmarks for such a
test (Fortes Francisco et al., 2015). Here we report the adaptation of
in vitro assay protocols (McCabe et al., 1983) that can be performed
on any T. cruzi strain without requiring sophisticated laboratory
equipment, and the activity proﬁling of a small panel of CYP51
inhibitors in these assays to investigate whether the clinical re-
lapses observed following posaconazole and fosravuconazole
therapies could have been predicted, at least partly, from these
simple in vitro surrogate assays.
2. Materials and methods
2.1. Cells and media
A T. cruzi Tulahuen C2C4 strain that expresses the b-galactosi-
dase gene (LacZ) (Buckner et al., 1996) was cultured in RPMI-1640
supplemented with 10% inactivated FBS (iFBS) and 2 mM L-gluta-
mine at 37 C and 5% CO2. L6 rat skeletal myoblast cells (ATCC CRL-
1458) were used as host cells for infection with transgenic T. cruzi
trypomastigotes.
2.2. Drugs
Nifurtimox, posaconazole, fenarimol, clotrimazole, econazole,
itraconazole, ketoconazole and tioconazole were purchased from
Sigma-Aldrich. Benznidazole was synthesized by Epichem Pty Ltd,
Murdoch, Australia. Stock solutions of these drugs were prepared in
DMSO 100% at 10 mg/ml and 1 mg/ml.
2.3. LacZ/CPRG assay
L-6 cells or murine peritoneal macrophages (MPM) were
seeded,1000 cells per well (L6) or 4000 cells per well (MPM), in 96-
well microtiter plates (Costar) in 100 ml RPMI 1640 with 10% heat-
inactivated FBS (Connectorate AG) and 2 mM L-glutamine at 37 C
and 5% CO2. At 24 h the medium was replaced by 100 ml fresh
medium containing 5000 (L6) or 4000 (MPM) trypomastigote
T. cruzi. At 72 h the medium was replaced by 100 ml (L6) or 200 ml
(MPM) fresh medium with serial drug dilution from
30,000e0.5 ng/ml in 3-fold steps. After 96 h incubation, the plates
were inspected microscopically, followed by the addition of CPRG/
Nonidet solution (0.25 mM Chlorophenol red-b-D-galactopyrano-
side and 0.25% Nonidet in PBS; 50 ml per well). After 5 h further
incubation, the plates were read photometrically at 540 nm; IC50
and IC90 values as well as the Hill factor were calculated by the four
parameter nonlinear regression model using the software Softmax
Pro (Molecular Devices Cooperation, Sunnyvale, CA, USA). All values
are means from at least three independent assays.2.4. Giemsa assay
4000 MPM were seeded into 16-chamber slides (Lab-tek)
(McCabe et al., 1983). Incubation, infection with trypomastigote
T. cruzi at MOI of 1, and drug exposure were performed as described
above. After the 96 h drug exposure the mediumwas removed and
the slides were ﬁxed with methanol for 10 min, followed by
staining with 10% Giemsa solution (Sigma). The infection status
(infected/non-infected) of at least 400 cells was determined
microscopically. If possible, the number of intracellular amastigotes
was counted for 100 infected cells. At low infection rates, the
number of intracellular amastigotes was determined for all infected
cells. The infection rates of the untreated controls were between
85% and 95%. The results were expressed either as a percentage of
infected host cells compared to untreated controls, or as mean
numbers of amastigotes per infected macrophage. The T. cruzi
population size was calculated as the number of intracellular
amastigotes per 100 macrophages (% infection rate  number of
amastigotes per infected cell). IC50 and IC90 values, as well as the
Hill factor, were calculated from the sigmoidal dose-response curve
using the four parameter nonlinear regression model of the soft-
ware Softmax Pro (Softmax Pro Molecular Devices Cooperation,
Sunnyvale, CA, USA). All values are means from at least three in-
dependent assays. For assessment of cidality, the medium was
removed after 96 h drug exposure and the adherent MPM were
washed four times with 200 ml fresh medium. 200 ml fresh medium
was added, followed by a further 168 h incubation. The medium
was then removed, and the slides were ﬁxed with methanol and
stained with 10% Giemsa as described above.
3. Results and discussion
3.1. Myoblasts vs. macrophages as host cells
Trypanosoma cruzi can infect practically every type of nucleated
mammalian cell. Muscle cells, and cardiomyocytes in particular, are
among the cells targeted by T. cruzi that contribute to the pathology
of Chagas disease (Nagajyothi et al., 2012). Rat L6 arewidely used as
convenient and relevant host cells for testing compounds against
the intracellular amastigote stage of T. cruzi. The standard assay
requires 96 h exposure to a test compound followed by quantiﬁ-
cation of the parasites (Buckner et al., 1996). Longer incubation
times with this speciﬁc cell line are not possible because L6 cells
multiply with a population doubling time of about 15 h and the
cultures would overgrow. Instead, we used mouse peritoneal
macrophages as a non-dividing type of host cell. The infection rates
of the macrophages with T. cruzi trypomastigotes were over 80%.
The replication time of intracellular T. cruzi amastigotes is 18e20 h
and was determined in previous experiments. A selection of anti-
fungal CYP51 inhibitors, 6 azoles plus the non-azole fungicide
fenarimol, were tested against T. cruzi, along with the standard
drugs benznidazole and nifurtimox, in parallel in L6 cells and
macrophages. A LacZ transfected Tulahuen strain (C2C4) was used
for ease of read-out with the chromogenic b-galactosidase sub-
strate CPRG (Chlorophenol red-b-D-galactopyranoside). All CYP51
inhibitors had IC50 values in the low nanomolar range, whereas the
reference drugs benznidazole and nifurtimox were clearly less
potent, with IC50 values in the micromolar range (Table 1, left two
columns). Posaconazole was over 1000-fold more potent than
benznidazole in both systems (Table 1). The IC50 values of all
compounds tested were lower in macrophages than in L6 cells
(p ¼ 0.004; two-tailed Wilcoxon matched pairs test). IC90 values
could not be determined accurately (Table 1) as the variance at the
tail of the dose-response curvewas too high. Thus themacrophages
provided a highly sensitive test system, but the colorimetric signal
Table 1
In vitro drug sensitivity tests for T. cruzi. Values are the means of at least 3 replicates ± S.D. in nM (L6, rat L6 myoblasts; MPM, murine peritoneal macrophages; CPRG,
Chlorophenol red-b-D-galactopyranoside).
L6 MPM MPM MPM
96 h, CPRG 96 h, CPRG 96 h, giemsa 96 þ 168 h, giemsa
Benznidazole IC50 1800 ± 540 850 ± 190 4800 ± 1100 5800 ± 2900
IC90 6600 ± 2800 3100 ± 790 11,000 ± 650 18,000 ± 9700
Nifurtimox IC50 470 ± 160 180 ± 45 990 ± 200 1100 ± 720
IC90 2200 ± 760 770 ± 7 2700 ± 290 4300 ± 3900
Posaconazole IC50 0.7 ± 0.3 0.3 ± 0.07 46 ± 2.8 280 ± 460
IC90 57 ± 49 1.4 ± 1.0 >1400 >4300
Ketoconazole IC50 1.7 ± 1.5 0.4 ± 0.4 34 ± 35 n/a
IC90 67 ± 64 1.7 ± 0.4 >1900 n/a
Clotrimazole IC50 20 ± 15 1.7 ± 0.6 470 ± 440 4200 ± 520
IC90 310 ± 190 7.3 ± 2.9 >29,000 >29,000
Econazole IC50 60 ± 11 16 ± 5.2 320 ± 210 1100 ± 130
IC90 1300 ± 530 170 ± 24 18,000 ± 9500 >26,000
Tioconazole IC50 72 ± 10 10 ± 7.8 500 ± 410 1400 ± 110
IC90 970 ± 360 21 ± 26 >26,000 >26,000
Itraconazole IC50 5.7 ± 4.3 0.9 ± 0.4 99 ± 58 1200 ± 150
IC90 69 ± 51 5.7 ± 4.3 >1400 >14,000
Fenarimol IC50 160 ± 6.0 12 ± 9.1 540 ± 57 5700 ± 5000
IC90 >300 33 ± 39 >30,000 >30,000
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measuring signals close to background from small numbers of re-
sidual T. cruzi amastigotes.Fig. 1. In vitro drug sensitivity of T. cruzi amastigotes in mouse macrophages after
96 h drug exposure. The solid lines represent the azoles and the dashed lines
represent the reference drugs benznidazole and nifurtimox. The Hill factors (HF) of the
dose response curves are indicated in the legend. Percentage growth of the parasites as
quantiﬁed by colorimetric read-out of CPRG turn-over.3.2. b-galactosidase vs. giemsa staining as read-out
As a more accurate alternative to CPRG-based colorimetric
readout, we tested Giemsa staining followed by microscopic read-
out to determine numbers of infected macrophages and, for
selected compounds, the parasite load of infected cells. This more
labor-intensive method of detection allowed the speciﬁc identiﬁ-
cation and accurate counting of T. cruzi amastigotes at the single cell
level (see the Graphical Abstract for a sample image). The resulting
IC50 values based on the infection rate were more than an order of
magnitude higher than those determined by CPRG (Table 1). This
can be explained by the fact that Giemsa staining determined the
percentage of infected macrophages (regardless of the number of
intracellular amastigotes), whereas the ﬂuorescence signal from
CPRG turn-over is proportional to the total number of amastigotes
(regardless of the percentage of infected host cells). The IC values
derived by Giemsa were thus not proportional to the total number
of parasites, and the resulting IC50 values were comparably higher.
The IC90 values obtained by microscopic determination of the
infection rate following Giemsa staining are, however, in our
opinion more meaningful than those obtained with CPRG, because
single surviving amastigotes can be detected by microscopic
counting. Figs. 1 and 2A compare the two different kinds of dose-
response curves. The reference drugs benznidazole and nifurti-
mox exhibited a smaller shift in IC50 from a decrease in overall
parasitaemia (CPRG read-out) to a decrease in infected host cells
(Giemsa read-out) than the seven antifungals. Furthermore, the Hill
factors (HF) of the dose-response curves for the reference drugs
were higher for the Giemsa read-out while the CYP51 inhibitors
exhibited ﬂatter curves for the Giemsa read-out than for CPRG
(mean Hill factors of 0.90 vs. 1.8; p ¼ 0.047; two-tailed Wilcoxon
matched pairs test). Importantly, the Giemsa dose-response curves
of the reference drugs (Fig. 2A) reached base-line, while those of
the antifungals (Fig. 2A) did not. Thus none of the CYP51 inhibitors
tested led to a 100% clearance of parasitaemia from the infected cell
population-. A small percentage of host cells remained infected,
although with a very low parasite load of 1e4 parasites per infected
cell, compared to >10 parasites in untreated infected control cells.The parasite load of untreated cells was very high 96 h post
infection (>10 amastigotes/cell). For the purpose of Fig. 2B, the
average parasite load was counted up to 10 amastigotes/cell. The
drop in mean parasite load is reﬂected by the drop in the CPRG
signal. The CYP51 inhibitors showed a clear reduction of the para-
site load per infected cell, which settled at a low load (Fig. 2B). The
standard drug benznidazole tends to show a continuous reduction
of the parasite load. All compounds were tested to the maximum
non-cytotoxic concentration. In Fig. 2C, the calculated total number
of intracellular T. cruzi amastigotes in 100 macrophages is plotted
against drug concentration. This clearly shows the ﬂat dose-
response of CYP51 inhibitors and their inability to kill all para-
sites within 96 h of drug exposure. The drug exposure period of
96 h corresponds to 4e5 parasite generations. This should be long
enough for a complete depletion of the preformed pool of sterols,
which is a prerequisite for a cidal effect of the ergosterol biosyn-
thesis inhibitors (Urbina, 1998). However, we cannot exclude that
an even longer exposure would kill all the intracellular T. cruzi
Fig. 2. In vitro drug sensitivity of T. cruzi amastigotes in mouse macrophages after
96 h drug exposure. The solid lines represent the azoles and the dashed lines
represent the reference drugs benznidazole and nifurtimox. Hill factors (HF) of the
dose response curves are indicated in the legend. A) Percentage infected host cells as
quantiﬁed by microscopic read-out of Giemsa stains. B) Mean numbers of amastigotes
per infected macrophage as quantiﬁed by microscopic read-out of Giemsa stains. C)
Estimated numbers of intracellular amastigotes in 100 macrophages. Calculation: %
infection rate x mean number of amastigotes per infected cell.
Fig. 3. In vitro drug sensitivity of T. cruzi amastigotes in mouse macrophages after
drug washout (96 h) and 168 h recovery period. The solid lines represent the azoles
and the dashed lines represent the reference drugs benznidazole and nifurtimox. Hill
factors (HF) of the dose response curves are indicated in the legend. A) Percentage
infected host cells as quantiﬁed by microscopic read-out of Giemsa stains. B) Mean
numbers of amastigotes per infected macrophage as quantiﬁed by microscopic read-
out of Giemsa stains. C) Estimated numbers of intracellular amastigotes in 100 mac-
rophages. Calculation: % infection rate x mean number of amastigotes per infected cell.
M. Cal et al. / International Journal for Parasitology: Drugs and Drug Resistance 6 (2016) 165e170168amastigotes.We calculated that >10 parasites per 100macrophages
survive at the highest concentrations of CYP51 inhibitors. Benzni-
dazole showed a good dose-response curve and at a concentrationof 40 mM, only <1 parasite per 100 macrophages survived (Fig. 2C).
These results correlate with the previous observations made using
high content imaging technology in a panel of T. cruzi I-VI genotype
M. Cal et al. / International Journal for Parasitology: Drugs and Drug Resistance 6 (2016) 165e170 169strains (Moraes et al., 2014), validating the inability of CYP51 in-
hibitors to lead to full clearance of T. cruzi amastigote populations
following drug exposure, independent of the drug concentration
tested.
3.3. A long-term in vitro assay for sterile cidality
To assess whether these few residual intracellular T. cruzi
amastigotes were viable, we prolonged the in vitro test to a total
duration of 11 days. The drug-containing medium was removed
after 96 h incubation, the adherent macrophages were washed
twice, and fresh, drug free mediumwas added. After another 168 h
incubation, the numbers of infected macrophages, and for selected
compounds the parasite load of the infected cells, were determined
by Giemsa staining. For benznidazole and nifurtimox, the resulting
IC50 values only increased slightly (10e20%) compared to those
after 96 h (Table 1, right). In contrast, the majority of the CYP51
inhibitors tested exhibited a strong shift (>200%) in IC50 from 96 h
to 96þ 168 h tests. IC90 could not be determined, because the dose-
response curves of the CYP51 inhibitors did not reach background
levels. Fig. 3A illustrates the shift in IC values based on the per-
centage of infected cells. Fig. 3B and C shows the corresponding
mean number of intracellular amastigotes per infected cell and the
estimated total number of parasites per 100 macrophages,
respectively. The dose-response curves of the antifungals are ﬂat in
the 96 h drug exposure experiment (Fig. 2AeC) whereas the curves
are steeper in the wash-out experiment (Fig. 3AeC). The wash-out
experiments conﬁrmed that the few residual amastigotes observed
after 96 h incubation were viable and infective to other macro-
phages. Thus the tested antifungals posaconazole, clotrimazole,
econazole, tioconazole and itraconazole were not able to deliver
sterile cidality in vitro.
4. Conclusion
Mouse macrophages provide a highly sensitive system for
testing molecules in vitro against T. cruzi intracellular amastigotes.
Combined with Giemsa staining and microscopic read-out, this
system allows drug sensitivity tests over long periods of time with
high sensitivity and speciﬁcity, detecting single residual parasites.
Wash-out experiments demonstrated that these residual parasites
were alive and able to infect new host cells. When the percentage of
infected host cells was quantiﬁed by Giemsa staining, all the CYP51
inhibitors tested displayed lower IC50 values than the reference
drugs benznidazole and nifurtimox, but the dose-response curves
were much ﬂatter and did not reach baseline, showing that the
CYP51 inhibitors were unable to clear all T. cruzi amastigotes. This
indicates that measuring drug potency in terms of IC50 based on
viability markers is an insufﬁcient readout to predict for clearance
of parasitaemia in vitro and e by extension e in vivo, in particular if
the parasites are persistent and the compound's effect is rather
static than cidal. By using macrophages as host cells and Giemsa
staining as the read-out, it was indeed possible to demonstrate that
the azoles, as well as another non-azole based CYP51 inhibitors, do
not deliver sterile cidality deﬁned as full clearance of parasitaemia
in vitro. To evaluate the anti-T. cruzi potential of a compound, in our
opinion both the reduction in infection rate as well as the reduction
in the total number of parasites is important. The approach pre-
sented may provide early stage evidence e and potentially offer a
predictive preclinical toole for the observed parasitological relapse
of Chagas patients treated with azoles. The long-term incubation
assay, relying on mouse peritoneal macrophages as host cells and
Giemsa staining as the read-out, is not amenable to high
throughput screening. It can be implemented as a secondary assay
to proﬁle and eventually prioritize anti-T. cruzi hits identiﬁed fromscreening campaigns, or it may serve as the starting point for
developing a high-content assay amenable to higher throughput
screening. Wash-out experiments demonstrated that the T. cruzi
amastigotes that persist following in vitro drug exposure with
CYP51 inhibitors are viable and replicating. While we cannot
exclude that drugs which are unable to deliver sterile cidality
in vitro might still work in vivo thanks to the contribution of the
host's immune system or any other factor not captured under the
experimental conditions of our assay, we hope that the presented
assay will contribute to render the discovery cascade for Chagas
disease more predictable.
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